Clinical trial · Observational
Uveal Melanoma and Brachytheraphy: Long-term Outcomes.
Long-term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy
NCT04577742CI-TRIAL-00047572completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigated the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival in patients affected by uveal melanoma and undergoing Ru-106 plaque brachytherapy between February 2011 and March 2020
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| 106 Ruthenium Plaque Brachytherapy | — | UNRESOLVED | — |
| Uveal Melanoma | Uveal Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 106 Ruthenium plaque brachytherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate long-term outcomes in patients underwent brachytherapy for uveal melanoma
- timeFrame
- Mean follow-up was 4 years (3 months-9 years)
- description
- To investigate the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * age older than 40 years * diagnosis of uveal melanoma Exclusion Criteria: * age older than 80 years * No diagnosis of uveal melanoma
References
Publications (0)
Data not yet available
No reference posted for this study.